Skip to main content
. 2020 Mar 13;26:e918751-1–e918751-8. doi: 10.12659/MSM.918751

Figure 4.

Figure 4

Exo1 deficiency sensitize ovarian cancer resistant cells to cisplatin and doxorubicin. (A) Exo1 deficiency sensitize SKCR cells to cisplatin. WT Exo1 or Vector was expressed after 24 hours of siExo1 or Control transfection. Cisplatin was added after 24 hours of Exo1 or Vector expression. Cisplatin concentrations: 0, 0.078, 0.31, 1.25, 5, and 20 μM, respectively. (B) Exo1 deficiency sensitize SKDR cells to doxorubicin. Doxorubicin concentrations are 0, 0.78, 3.13, 12.5, 50, and 200 μM, respectively.